Learn about July 2025’s top biotech deals, featuring major collaborations in small molecules, antibodies, and drug delivery.

Sanofi’s shift to immunology, AI-driven R&D, and strong pipeline offset risks from patent cliffs and legal issues. See why ...

Sanofi has finalized its takeover of Vigil Neuroscience for roughly $470 million, acquiring all outstanding shares at $8 each and issuing a $2-pe ...

Sanofi SNY reported second-quarter 2025 adjusted earnings of 90 cents per American depositary share, which missed the Zacks ...

Sanofi Q2 sales rose 10.1% at constant currency, led by Dupixent and ALTUVIIIO. EPS missed estimates; 2025 sales guidance was revised upward.

In 2025, sales are anticipated to grow by a high single-digit percentage at CER (previously mid-to-high single-digit). Sanofi confirms the expectation of a strong business EPS rebound with growth at a ...

That's the top-line finding of the latest financing report from the UK BioIndustry Association (BIA), which reveals that ...

Last week, a US Food and Drug Administration (FDA) advisory committee (AdCom) voted against approval of Danish drugmaker ...

Since 2015, Giovanni Ferrero has expanded his family's company beyond brands like Nutella and built a global powerhouse—especially through big acquisitions in the U.S.

Celtics’ New Trade Acquisition Sends Message to Upset Fans originally appeared on Athlon Sports. After falling short of their goal to win back-to-back NBA championships, the Boston Celtics made ...

Trading Pavel Zacha could lighten the financial load for Boston to acquire one of the best faceoff forwards in the NHL.

A roundup of the most newsworthy healthcare press releases from PR Newswire this week, including Sanofi's $1.6B acquisition and a groundbreaking surgical nerve treatment for veterans. NEW YORK ...